Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM

Rhea-AI Summary

The Alberta Government now covers the Dexcom G7 Continuous Glucose Monitoring (CGM) System for eligible residents with type 1 or type 2 diabetes. Dexcom G7 has been added to the Alberta Drug Benefit List, expanding eligibility to include adults aged 18 and older. Residents under 18 must require ongoing insulin or insulin pump therapy, while those 18 and older must use an insulin pump, basal and bolus insulin, or premixed insulin. Dexcom G7 is designed to simplify diabetes management and lower A1C levels. The system offers features like quick sensor warm-up, predictive Urgent Low Soon alerts, and compatibility with various digital health apps. This move aligns Alberta with other Canadian regions, enhancing access to CGM technology. For more information, visit Dexcom's website.

Positive

• Alberta Government now covers Dexcom G7 for eligible residents with type 1 or type 2 diabetes.
• Eligibility expanded to include adults aged 18 and older.
• Dexcom G7 added to the Alberta Drug Benefit List.
• Dexcom G7 helps simplify diabetes management and lower A1C levels.
• Enhanced access to CGM technology in Alberta aligns with other Canadian regions.

Negative

• None.

Insights

Healthcare Market Analyst

The expansion of CGM coverage in Alberta represents a significant market opportunity for Dexcom. Lifting age restrictions and including both Type 1 and Type 2 diabetes patients substantially broadens the addressable market. With Alberta joining six other Canadian provinces/territories in providing broader CGM coverage, this demonstrates growing nationwide acceptance of CGM technology as a standard of care. The coverage expansion particularly benefits Dexcom's market position by including adult patients on various insulin regimens, not just insulin pump users. This development aligns with the broader trend of increasing CGM adoption and could accelerate Dexcom's revenue growth in the Canadian market.

Medical Device Analyst

The Dexcom G7's inclusion in Alberta's Drug Benefit List strengthens the company's competitive position in the CGM market. Key technical advantages highlighted include quick sensor warm-up time and predictive Urgent Low Soon alerts. The system's compatibility with various digital health apps enhances its value proposition. Clinical validation showing improved A1C outcomes for both Type 1 and Type 2 diabetes patients adds credibility to the reimbursement decision. This coverage expansion could serve as a template for remaining Canadian provinces and territories, potentially leading to broader national coverage.

Alberta Government is now covering Dexcom G7, providing eligible residents living with either type 1 or type 2 diabetes with increased access to the life-changing technology

BURNABY, British Columbia--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the eligibility criteria* to also include adults ages 18 and older.

Alberta residents living with type 1 or type 2 diabetes who meet the eligibility criteria are now covered for Dexcom G7 (Photo: Business Wire)

Alberta residents living with type 1 or type 2 diabetes who are enrolled in a government-sponsored health benefit plan^† and meet the eligibility criteria* below may now receive coverage for Dexcom G7:

• Under 18 years of age: requiring the ongoing use of any insulin OR insulin pump therapy.
• 18 years of age and older: requiring the ongoing use of insulin pump therapy, OR a basal and bolus insulin, OR a premixed insulin.

“Canadians living with any type of diabetes understand the challenges that come with management of the condition. Dexcom G7 has been designed to make daily management easier and to help improve users' day-to-day lives – whether they’re a recently diagnosed adolescent or an adult who’s lived with the condition for decades,” said André Côté, Vice President and General Manager of Dexcom Canada. “We’re thrilled that the government of Alberta recognizes this and is introducing public coverage for eligible residents that includes both adults and children living with type 1 or type 2 diabetes on intensive insulin therapy.”

Dexcom G7 offers a better way to help users gain greater control of their glucose levels and is clinically proven to lower A1C for people living with type 1 diabetes and type 2 diabetes.^1-5 Features like its quick sensor warm-up time, a predictive Urgent Low Soon alert, and wide range of compatible digital health apps differentiate it amongst other available CGM systems in Canada, providing users with a simple, accurate⁶ and effective way to manage their diabetes day-to-day.

"The importance and value of continuous glucose monitoring (CGM) for people living with diabetes requiring insulin treatment is underscored by Canadian and international clinical practice guidelines," said Dr. Peter Senior, Endocrinologist and Director of the Alberta Diabetes Institute. "As a diabetes specialist working with patients, I have seen the benefits of CGM and the challenges faced by those who couldn’t afford it. Ensuring equitable access to CGM technology is a significant and important step forward for diabetes care in Alberta.”

Across Canada, coverage for Dexcom’s leading CGM technology has grown significantly over the last few years. This announcement brings Alberta on par with British Columbia, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island and Yukon in terms of making diabetes technology like Dexcom CGM available to a broader group of those who can benefit from it.

Albertans on any type of insulin who have private insurance or are covered by the Non-Insured Health Benefits (NIHB) federal program have access to Dexcom G7 through those plans.^‡.

To learn more about Dexcom G7 and details about public or private insurance plan coverage, please visit https://www.dexcom.com/en-CA/coverage.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

_______________________________________

1 Beck RW, et al. JAMA. 2017;317(4):371-378.
2 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.
3 Martens T, et al. JAMA. 2021;325(22):2262-2272.
4 Laffel LM, et al. JAMA. 2020;323(23):2388-2396.
5 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7.
6 Dexcom, data on file, 2024.

* For detailed coverage criteria, please visit https://www.dexcom.com/en-ca/coverage/alberta-health-provincial-cgm-coverage.
† To view a list of eligible government-sponsored health benefit plans, please visit https://idbl.ab.bluecross.ca/idbl/drugDetails?_cid=eef94732-04fd-42e1-8e66-68cfae3b60cb&id=0000111639&intchg_grp_nbr=1&detailId=12573683.
‡ Eligibility and coverage vary by policy, plan, and payor.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241217145216/en/

Media Contact:

Cheyenne Freitas

freitas@veritasinc.com

647-985-4806

Source: Dexcom, Inc.

FAQ

What does the Alberta Government's coverage of Dexcom G7 mean for DXCM shareholders?

The Alberta Government's coverage of Dexcom G7 expands the market for Dexcom's products, potentially increasing revenue and positively impacting DXCM shareholders.

Who is eligible for Dexcom G7 coverage in Alberta?

Alberta residents with type 1 or type 2 diabetes who meet specific criteria, including those under 18 requiring insulin or insulin pump therapy, and adults 18 and older using insulin pump, basal and bolus insulin, or premixed insulin.

How does Dexcom G7 benefit diabetes management?

Dexcom G7 simplifies diabetes management by offering features like quick sensor warm-up, predictive Urgent Low Soon alerts, and compatibility with various digital health apps, helping to lower A1C levels.

What are the new eligibility criteria for Dexcom G7 coverage in Alberta?

The new criteria include residents under 18 needing insulin or insulin pump therapy and adults 18 and older using insulin pump, basal and bolus insulin, or premixed insulin.

How does the coverage of Dexcom G7 in Alberta compare to other Canadian regions?

The coverage in Alberta now aligns with British Columbia, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island, and Yukon, enhancing access to CGM technology across these regions.

Where can I find more information about Dexcom G7 coverage in Alberta?

More information about Dexcom G7 coverage in Alberta can be found on Dexcom's website.